Evidence map›Paper›PMID 28533937›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2017

A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of

Shadi A Esfahani, Stephanie Salcedo, Pedram Heidari, Onofrio A Catalano, Rachel Pauplis, Jacob Hesterman, James F Kronauge, Umar Mahmood

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Safety and accuracy ofAmerican journal of nuclear medicine and molecular imaging · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shadi A EsfahaniAthinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, USA.
Stephanie SalcedoAthinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, USA.
Pedram HeidariAthinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, USA.
Onofrio A CatalanoAthinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, USA.
Rachel PauplisInviCRO LLC, 27 Drydock Ave.Boston 02210, MA, USA.
Jacob HestermanInviCRO LLC, 27 Drydock Ave.Boston 02210, MA, USA.
James F KronaugeInviCRO LLC, 27 Drydock Ave.Boston 02210, MA, USA.
Umar MahmoodAthinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, USA.
Athinoula A. Martinos Center for Biomedical Imaging · USInvicro (United States) · US

Funding

PET imaging of carcinoid tumors to guide individualized chemotherapyR01CA166582 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MAHMOOD, UMAR · 2013 to 2017
$1.8M
NCI NIH HHS R01 CA166582
6 · The paper itself

Abstract

This prospective pilot study provides a dynamic whole body PET/MR image database, clinical safety, biodistribution profile and dosimetry of

Indexed as

68GadosimetryDOTATOCPET/MRsafetysomatostatin receptor

Identifiers

PMID28533937
PMCPMC5435611
OpenAlexW3023663032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.